Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Lands FDA Clearance, CE Mark for Synct Software

NEW YORK (GenomeWeb) – Luminex announced today that it has received approvals from US and European regulators for the Synct software that connects its molecular diagnostic platforms.

The Austin, Texas-based firm has received clearance from the US Food and Drug Administration and CE Marking for its Synct software, which connects its Aries platform with NxTag assays run on its multiplex Magpix System. The software provides access to data and reports from both systems on a single interface. For labs running Aries and NxTag assays, the software offers a streamlined workflow, enhanced data management, and the ability to easily add new functionality, Luminex said in a statement. Synct can even connect instruments across multiple locations and send all results to a single reviewer.

Luminex VP of Global Marketing Eric Shapiro added that it would provide molecular labs "a better way to manage their data while reducing operational costs."

Luminex had previously received FDA clearance and CE-IVD marking for its NxTag Respiratory Pathogen Panel and has received FDA clearance for its Aries system and herpes assay.